Q-omics provides the consensus-scored LGALSL-DT profile across patient tissues and cancer cell-line models. LGALSL-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LGALSL-DT is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, LGALSL-DT RNA expression shows 16,930 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, LUAD, and ACC as cancer lineages where LGALSL-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALSL-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALSL-DT survival associations across molecular data types. LGALSL-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALSL-DT RNA expression–survival associations across cancer types. High LGALSL-DT expression shows unfavorable associations in COAD, ACC and LIHC, but favorable associations in PAAD, KIRC and ESCA. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LGALSL-DT RNA expression.
This table summarizes LGALSL-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LGALSL-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALSL-DT shows lower tumor expression in LUAD, KICH, BRCA and LUSC and higher tumor expression in LIHC and CHOL. The LUAD box plot shows higher LGALSL-DT RNA expression in normal versus tumor tissue (log2 FC = −1.013, t-test p < 0.001).
This table shows molecular features associated with LGALSL-DT in patient tissues and cancer cell lines. In patient samples, LGALSL-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
